Cargando…

TKI sensitivity patterns of novel kinase-domain mutations suggest therapeutic opportunities for patients with resistant ALK+ tumors

The anaplastic lymphoma kinase (ALK) protein drives tumorigenesis in subsets of several tumors through chromosomal rearrangements that express and activate its C-terminal kinase domain. In addition, germline predisposition alleles and acquired mutations are found in the full-length protein in the pe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amin, Amit Dipak, Li, Lingxiao, Rajan, Soumya S., Gokhale, Vijay, Groysman, Matthew J., Pongtornpipat, Praechompoo, Tapia, Edgar O., Wang, Mengdie, Schatz, Jonathan H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5029658/ https://www.ncbi.nlm.nih.gov/pubmed/27009859 http://dx.doi.org/10.18632/oncotarget.8173

Ejemplares similares

Oncogene Overdose: Too Much of a Bad Thing for Oncogene-Addicted Cancer Cells
por: Amin, Amit Dipak, et al.
Publicado: (2015)

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447
por: Peters, Tara L., et al.
Publicado: (2016)

Synergistic Induction of Apoptosis in High-Risk DLBCL by BCL2 Inhibition with ABT-199 Combined With Pharmacologic Loss of MCL1
por: Li, Lingxiao, et al.
Publicado: (2015)

Kinase overexpressing cancers responsive to drug withdrawal
por: Amin, Amit Dipak, et al.
Publicado: (2015)

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
por: Zhu, Qian, et al.
Publicado: (2017)

The Mechanism of Cancer Drug Addiction in ALK-Positive T-Cell Lymphoma
por: Rajan, Soumya S., et al.
Publicado: (2019)

Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?
por: Amin, Amit Dipak, et al.
Publicado: (2017)

Holistic View of ALK TKI Resistance in ALK-Positive Anaplastic Large Cell Lymphoma
por: Wang, Yuan, et al.
Publicado: (2022)

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations Followed by Epithelial-Mesenchymal Transition
por: Urbanska, Edyta M., et al.
Publicado: (2020)

High Throughput Sequential ELISA for Validation of Biomarkers of Acute Graft-Versus-Host Disease
por: Fiema, Bryan, et al.
Publicado: (2012)

Case report: Epithelioid inflammatory myofibroblastic sarcoma treated with an ALK TKI ensartinib
por: Li, Mengmeng, et al.
Publicado: (2023)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Acquired ALK Resistance Mutations Identified from Liquid Biopsy in an ALK-Rearranged Squamous Cell Lung Cancer Patient Treated with Sequential ALK TKI Therapy: A Case Report
por: Yao, Bin, et al.
Publicado: (2021)

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
por: Ouseph, Madhu M, et al.
Publicado: (2019)

Response to treatment with an ALK-TKI in a patient with advanced lung adenocarcinoma with concurrent ALK fusion and high PD-L1 expression: A case report
por: Zhang, Yaping, et al.
Publicado: (2022)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Real-World Data on EGFR and ALK Testing and TKI Usage in Norway—A Nation-Wide Population Study
por: Eide, Inger Johanne Zwicky, et al.
Publicado: (2023)

An Opportune Suggestion
Publicado: (1914)

Involvement of the TNF-α Pathway in TKI Resistance and Suggestion of TNFR1 as a Predictive Biomarker for TKI Responsiveness in Clear Cell Renal Cell Carcinoma
por: Hwang, Hee Sang, et al.
Publicado: (2020)

A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
por: Du, Jia, et al.
Publicado: (2022)

Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report
por: Wang, Hongbiao, et al.
Publicado: (2022)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer
por: Fang, Yisheng, et al.
Publicado: (2021)

MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities
por: Qin, Kang, et al.
Publicado: (2023)

A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy
por: Dower, William J., et al.
Publicado: (2023)

Protocol for a phase II randomised controlled trial of TKI alone versus TKI and local consolidative radiation therapy in patients with oncogene driver-mutated oligometastatic non-small cell lung cancer
por: Tibdewal, Anil, et al.
Publicado: (2021)

Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma
por: Zdzalik, Daria, et al.
Publicado: (2014)

Bioinformatic mapping of AlkB homology domains in viruses
por: Bratlie, Marit S, et al.
Publicado: (2005)

The TKI Era in Chronic Leukemias
por: De Novellis, Danilo, et al.
Publicado: (2021)

Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
por: Stadler, Serena, et al.
Publicado: (2018)

Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report
por: Falk, Markus, et al.
Publicado: (2023)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
por: Zhao, Lihao, et al.
Publicado: (2019)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
por: Lovisa, Federica, et al.
Publicado: (2015)

Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
por: Damm-Welk, Christine, et al.
Publicado: (2016)

TrkA is a binding partner of NPM‐ALK that promotes the survival of ALK (+) T‐cell lymphoma
por: Shi, Wenyu, et al.
Publicado: (2017)

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases
por: Wang, Chunyu, et al.
Publicado: (2019)

CT-Based Radiomic Signature as a Prognostic Factor in Stage IV ALK-Positive Non-small-cell Lung Cancer Treated With TKI Crizotinib: A Proof-of-Concept Study
por: Li, Hailin, et al.
Publicado: (2020)

ALK and NSCLC: Targeted therapy with ALK inhibitors
por: Hallberg, Bengt, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_5fsiai6i6e1svdrlilqsnl91n4